Generic placeholder image

Anti-Cancer Agents in Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1871-5206
ISSN (Online): 1875-5992

Targeting JAK3 Tyrosine Kinase-Linked Signal Transduction Pathways with Rationally-Designed Inhibitors

Author(s): Fatih M. Uckun, Alexei Vassilev, Ilker Dibirdik and Heather Tibbles

Volume 7 , Issue 6 , 2007

Page: [612 - 623] Pages: 12

DOI: 10.2174/187152007784111304

Price: $65

Abstract

Inhibitors of Janus Kinase 3 (JAK3) show potential as a new class of apoptosis-inducing anti-cancer drugs. In addition, JAK3 inhibitors may also be useful as immunosuppressive agents. Rationally designed selective inhibitors of JAK3 such as JANEX-1, that do not inhibit other Janus kinases have recently undergone extensive preclinical testing that revealed a favorable pharmacodynamic profile. Here we discuss the clinical potential of targeting JAK3-linked signal transduction pathways with small molecule inhibitors such as JANEX-1.

Keywords: Rational Drug Design, Tyrosine Kinases, Inhibitors, JAK3


Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy